



REVIEW ARTICLE

The Risks of Renal Angiomyolipoma: Reviewing the Evidence

Raouf M. Seyam, Waleed K. Alkhdair, Said A. Kattan, Mohamed F. Alotaibi, Hassan M. Alzahrani, Waleed M. Altaweel

Department of Urology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

Abstract

Renal angiomyolipoma (RAML), though a rare benign tumor, may impose a significant morbidity or even mortality due to its unique characteristics and the complications subsequent to its treatment. The classic tumor variant is composed of smooth muscular, vascular, and fatty components. The most straightforward diagnosis is when the fat component is abundant and gives a characteristic appearance on different imaging studies. In fat-poor lesions, however, the diagnosis is difficult and presumed a renal cell carcinoma. Yet, some variants of RAML, though rare, express an aggressive behavior leading to metastasis and mortality. The challenge lies in the early detection of benign variants and identifying aggressive lesions for proper management. Another challenge is when the vascular tissue component predominates and poses a risk of hemorrhage that may extend to the retroperitoneum in a massive life-threatening condition. The predicament here is to identify the characteristics of tumors at risk of bleeding and provide a prophylactic treatment. According to the clinical presentation, different treatment modalities, prophylactic or therapeutic, are available that span the spectrum of observation, embolization, or surgery. Renal impairment may result from extensive tumor burden or as a complication of the management itself. Improvement of diagnostic techniques, super-selective embolization, nephron-sparing surgery, and late treatment with the mammalian target of rapamycin inhibitors have provided more effective and safe management strategies. In this review, we examine the evidence pertaining to the risks imposed by RAML to the patients and identify merits and hazards associated with different treatment modalities.

Keywords: angiomyolipoma; embolization; hemorrhage; kidney; nephrectomy

Received: 04 August 2017; *Accepted after revision:* 23 September 2017; *Published:* 16 October 2017.

Author for correspondence: Raouf M. Seyam, Department of Urology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. Email: rmseyam@yahoo.com

How to cite: Seyam RM et al. The risks of renal angiomyolipoma: Reviewing the evidence. *J Kidney Cancer VHL* 2017;4(4): 13–25

Doi: <http://dx.doi.org/10.15586/jkcvhl.2017.97>

Copyright: Seyam RM et al.

License: This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). <http://creativecommons.org/licenses/by/4.0>

Introduction

Renal angiomyolipoma (RAML) is a rare benign tumor that has acquired much attention because of the risks it poses to patients and sometimes due to its ability to mimic renal cell cancer (RCC) (1–5). Sporadic RAMLs (sRAML) are smaller than their tuberous sclerosis (TSC)-associated counterparts, usually unilateral and risk bleeding only when large.

The indications of treatment in symptomatic patients include hemorrhage and pain. Asymptomatic patients are treated to mitigate the risk of bleeding, for the suspicion of malignancy, and to prevent renal impairment. The management of RAML has changed over the years: while early treatment was nephrectomy, later a more conservative approach utilizing embolization and nephron sparing surgery (NSS), and finally

the mammalian target of rapamycin (mTOR) inhibitors has been proved effective to halt and reverse TSC-associated RAML (TSC-RAML) (2, 3). The caveats of intervention are mainly loss of renal tissue and function, while mTOR inhibition is effective only during the time of treatment. RAML itself or its treatment may cause significant morbidity and mortality to patients. In this article, we examine the evidence supporting the concerns raised by the medical community that justify prophylactic treatment or intervention. Meanwhile, we review the efficacy and safety of management, whether prophylactic or therapeutic.

Risk of Bleeding

Emergency treatment of bleeding associated with RAML continues to be a challenge to save the patient while preserving renal function. Several studies concluded that large lesions >4 cm and TSC-associated lesions are more susceptible to bleeding, raising the need for prophylactic management.

Acute bleeding

The most common cause of retroperitoneal bleeding of non-traumatic renal origin, sometimes responsible for fatality, is RAML followed by RCC (6, 7). Retroperitoneal hemorrhage is associated with large lesions (1, 8), spontaneous rupture of RAML (9), rupture of aneurysms (10, 11), associated with pregnancy (12, 13), trauma even trivial (14–16) and anticoagulation (17, 18). The management of bleeding RAML initially was nephrectomy (1, 5). A 10-year experience in the treatment of RAML favored nephrectomy or partial nephrectomy (PN) in 71.2% of patients and embolization in 28.8% (5). As technology evolved, embolization became the treatment of choice, leaving nephrectomy only for failed embolization in the emergency setting, development of post-embolization complications, and life-threatening hemorrhage (19–21). Embolization is associated with a high clinical success rate more than 90% (22, 23). Successful control of a bleeding emergency was reported in 96–100% of patients (20, 24). Bleeding occurs in both sporadic and TSC-associated lesions. A pooled analysis identified 441 patients with sRAML with a mean initial lesion diameter of 6.5 cm (25). Major retroperitoneal bleeding occurred in 12.2% of the patients, and the intervention rate was high for the whole group including 58.1% nephrectomy or PN, 29% embolization, and 7.3% conservative treatment. Active treatment was frequently reported (67.5%) in 400 patients with RAML, whereas the remaining 130 patients, 78.5% of whom were asymptomatic, underwent active surveillance (26). There is a consensus that symptomatic RAML mainly due to hemorrhage should be treated by embolization and surgical excision as a second-line treatment (27, 28).

Prophylaxis against bleeding

There is controversy regarding prophylactic management of asymptomatic RAML. Active surveillance in patients with

small lesions (mean size 1.7 cm) was associated with low growth rate (0.088 cm/year) and minimal (7%) secondary intervention (29). Larger lesions may be at high risk of bleeding, but there is no consensus on what size should be used as a cutoff for prophylaxis (27). Although in the pediatric age group, the incidence of RAML in TSC patients is 50.3%, growth rates are unpredictable and require only radiological follow-up (30). In that study, while management of the renal lesions in 145 patients was not consistent, fortunately none of the patients developed retroperitoneal hemorrhage.

Several options are available for prophylaxis, ranging from observation up to surgery (Table 1). The most drastic prophylaxis is total nephrectomy for large lesions (5) (Supplementary Table 2; the supplementary tables of this article are available on the journal's website, which can be accessed via the following link: <http://jkcvhl.com/index.php/jkcvhl/rt/suppFiles/97/0>). A surgeon's preference might be driven by the less demanding procedure compared to PN. Guidelines recommend that nephrectomy in TSC patients should be avoided (31). Prophylactic PN is contemplated by urologists as it provides a “permanent cure” of the resectable lesions, can be performed using minimally invasive surgery either laparoscopic or robotic assisted, and is associated with preservation of renal function (4, 5, 29, 32–41) (Supplementary Table 2). Surgical complications up to 21% were reported (5, 32, 33, 35, 36, 38). Only one patient out of 132 in four studies developed renal failure in a follow-up of 26 months to 8 years (32, 33, 36). No recurrence or a maximum recurrence rate of 3.4% developed at long-term follow-up (29, 32, 33, 35, 36, 38). The most recent advent of NSS is robotic PN (RPN). Three series included prophylactic RPN reported mostly low-grade complications, preservation of renal function, and no recurrence of lesions (39–41). Prophylactic embolization of RAML has been widely used with 85–91% success rate (22, 42–45) (Supplementary Table 3). The aim of prophylactic treatment is to devascularize the lesion and reduce its size. Several studies reported a mean size reduction of 25–72% (46–49). No bleeding or need for surgical intervention was required in up to 17% of patients (8, 43, 44, 46, 49, 50). The caveat of this approach is the need of multiple retreatments (8, 22, 42, 43, 47, 50). The highest reported complication rate was 19.5% (4, 8, 42, 44, 48). There is a risk of deterioration of the function of the treated renal unit; however, several studies showed no significant change in serum creatinine during a follow-up of 23–60 months (8, 44, 49, 50). Observation and active surveillance are viable options for patients who do not need active treatment (26, 29, 51–55) (Supplementary Table 4). Follow-up for 40–60 months was associated with no bleeding or size change (54, 55), growth in 8% (53), and need for intervention in 5.6–13% (26, 29, 52) or surgery in 29% (51). Observation for TSC-AML showed an association between severe hemorrhage and lesions >3.5 cm affecting 20% of patients prospectively followed for 60 months (56). Others showed a lower rate of hemorrhage and slow growth rate at 48 months (34). The studies of everolimus for the treatment of TSC-AML patients

Table 1. Summary of selected series which included prophylactic management against the risk of bleeding.

Method	Lesions	Follow-up duration (months)	Complications	Outcome	References
NSS	sRAMP/TSC-AML	15–96	0–21.4%	Preservation or renal function, rare renal impairment, recurrence 0–3.4%	(4, 5, 29, 32–38)
RPN	sRAMP/TSC-AML	8–40	15–26% including Clavien Grade I–II	eGFR preservation and no recurrence	(39–41)
Embolization	sRAMP/TSC-AML	20–85	multiple retreatments reported between 12 and 50%, complication rate varied between 0 and 19.5%	85–91% success rate, a mean size reduction of 25–72%, no bleeding or need for surgical intervention was required in 0–17%, no significant change of serum creatinine	(4, 8, 22, 42–50)
Observation	sRAMP/TSC-AML	40–60		No bleeding or size change, growth in 8%, need for intervention in 5.6–13% or surgery in 29%	(26, 29, 51–55)
Everolimus	TSC-AML	9.5–29	2 patients discontinued treatment because of adverse events, adverse events mostly grades 1–2	42–54% clinical response (size reduction >50%), no bleeding reported in patients or controls	(2, 57)

AML, angiomyolipoma; eGFR, estimated glomerular filtration rate; NSS, nephron sparing surgery; RPN, robotic partial nephrectomy; sRAML, sporadic renal AML; TSC, tuberous sclerosis complex.

reported a significant reduction in lesion size and no bleeding at follow-up, rendering the medication an important prophylactic option (2, 57) (Supplementary Table 5).

For asymptomatic patients, the European Association of Urology guidelines recommend surveillance and for high-risk patients embolization, PN, nephrectomy, or everolimus, albeit, with a weak evidence supporting any of these choices (27). High risk includes large lesion (size disputed), women in childbearing age and inadequate access to follow-up, or emergency service. For asymptomatic patients with TSC-RAML, guidelines from the 2012 TSC Consensus Conference recommended mTOR inhibitors as first-line short-term prophylactic treatment for patients with asymptomatic lesions >3 cm with category 1 recommendation (28). Second-line prophylactic procedures include embolization and NSS.

Several descending views challenge prophylaxis in asymptomatic patients. In patients with TSC, one study reported a

slow growth rate of RAML, with a mean inclusion mass of 3.6 cm and a median follow-up of 4 years (34). Asymptomatic lesions <4 cm can be followed up conservatively and rarely will become complicated (53). Following patients, mostly asymptomatic, treated by active surveillance for a mean of 40 months, only 13% required active treatment (26). Risk factors for the need of delayed intervention were tumor size ≥4 cm and having symptoms at diagnosis. Even larger lesions in asymptomatic patients were successfully managed only by observation (54). Follow-up of 22 renal units in asymptomatic patients, with four lesions 4–10 cm in diameter, showed no bleeding and only one progression in size at a mean duration of 3.8 years.

Another study recommended only surveillance for all asymptomatic patients with sRAML regardless of size as the natural history of these lesions has not been well characterized and the annual growth rate of lesions is extremely

slow (52). The analysis included patients with RAML ($n = 447$) who had three or more radiologic imaging. Regardless of size, RAML was stable with no appreciable growth at a median follow-up of 43 months. It is noteworthy, however, that the median size of the lesions was 1 cm and 90% of the patients had lesions ≤ 4 cm. In addition, of the 47 patients with lesions >4 cm, 38% ($n = 18$) had an intervention. From the larger cohort ($n = 2741$), seven patients with lesions >4 cm were excluded and had a nephrectomy or PN because of bleeding ($n = 3$), pain ($n = 1$), or electively ($n = 3$). Recalculating interventions for lesions >4 cm, 53.2% of patients required an intervention or surgery. From these data, one may conclude that more than 90% of patients with RAML ≤ 4 cm did not need an intervention, whereas more than half of patients with lesions >4 cm had an intervention or surgery.

Pregnancy and risk of bleeding

RAML and pregnancy constitute a challenging situation. In the absence of a large series, the risk of bleeding remains not well defined. Case reports imply that an accelerated growth of RAML may occur during pregnancy and subsequent pregnancies may have a higher chance of hemorrhagic complications warranting prophylactic treatment (12, 13). Bleeding may prompt emergency treatment. Conservative management and elective caesarian section were reported when the patient was asymptomatic, hemodynamically stable, or could be stabilized by blood transfusions (58–61). Treating a bleeding lesion by nephrectomy or PN may compromise the continuation of pregnancy (62). Meanwhile, case reports of embolization and nephrectomy during pregnancy with uneventful outcome were reported (63, 64). A literature review found 21 cases of bleeding RAML managed during pregnancy in the past 35 years (62). The reported management included conservative treatment in eight women, embolization in five women, and nephrectomy in seven women. Related fetal death was reported in two cases. The hemorrhagic shock itself may lead to fetal demise (65). Few cases were reported where embolization was used to treat the pregnant mother (63, 64, 66). The risk of fetal exposure to radiation must be considered. Once the mother has reached full term, the preferred method of delivery is through caesarian section. Cases were reported of RAML rupture, retroperitoneal hemorrhage, and acute abdomen during or immediately after vaginal delivery (67, 68). One case was reported with uneventful course after vaginal delivery in a patient treated conservatively for RAML rupture (69). Other challenging special conditions were reported and successfully managed (70–74).

mTOR inhibitors and bleeding

Several studies showed that mTOR inhibition results in a clinically significant reduction of TSC-RAML with acceptable tolerability and safety (2, 3, 75, 76). In 2012, everolimus was approved for the treatment of TSC-RAML. Treatment with

everolimus for 1 year resulted in a reduction of the size of renal lesions by at least 50% in 53.3% of patients (77). These findings were confirmed in a clinical trial involving patients with TSC-RAML of at least 3 cm diameter (2). The clinical response rate was 42%. In an open label extension of the trial at a median follow-up of 29 months, the response rate increased to 54% (57). No patient developed bleeding from the kidney during the trial or its extension. A meta-analysis suggested that everolimus treatment prevented bleeding in those patients (78). As the risk of bleeding is associated with larger lesion, it could be inferred that treatment with everolimus will decrease the risk of bleeding by size reduction. However, there was no reported direct evidence that everolimus did decrease the risk of bleeding in TSC patients compared to controls (2). Being an oral medication that is generally well tolerated, everolimus is an attractive alternative for prophylaxis against renal hemorrhage with the caveats of adverse events (AE) related to its immunosuppression and metabolic effects (60). mTOR therapeutic effect is reversed after cessation of treatment (75). Recommendations regarding the long-term duration of treatment have not been established. Additional everolimus benefits that may tip the balance in its favor are its concomitant therapeutic effect on brain lesions and safety on renal function. Everolimus has not been approved for the treatment of sRAML regardless of its size or associated risks.

Renal Malignancy

The issue of renal malignancy arises when a fat-poor AML is encountered, AML harboring RCC components is suspected of, or an epithelioid variant of the AML is present.

Fat-poor AML

RAML has a characteristic radiologic appearance based on its fat content. A fat-poor renal mass is treated as RCC, usually by PN or total nephrectomy depending on surgical feasibility. The diagnosis of RAML in this situation is post surgery. In a large series of 730 patients, fat-poor AML constituted 4.8% of lesions <4 cm surgically excised with a preoperative diagnosis of renal cancer (79). In another large series of patients treated surgically, fat-poor AML was found in 33–65% of lesions, most commonly in small single lesions and least commonly in TSC-associated lesions (80). Consequently, preoperative diagnosis may prevent unnecessary surgery for a low-risk RAML. An attempt at preoperative diagnosis utilized a modification of imaging techniques and patient characteristics (79). Fat-poor AML tends to occur with smaller lesions, female gender, and younger age (79). Imaging modifications and novel image analysis try to demonstrate the presence of a minute amount of fat within the lesion. Such techniques include ultrasound (81), computed tomography (82, 83), and magnetic resonance imaging (MRI) (84–88). Preoperative diagnosis is possible by transcutaneous biopsy.

The presence of fat, HMB-45 markers, or smooth muscle histologic markers discloses the diagnosis. The indications of special imaging or biopsy to rule out fat-poor RAML have not been well defined. When does the managing physician suspect AML rather an RCC for a solid renal lesion? We propose that such situations may include the association with TSC, the presence of multiple lesions, association with triphasic AML lesions, history of AML, and inconclusive radiological diagnosis.

Renal cell carcinoma

The development of RCC within a RAML is rare but possible. Follow-up of mass growth, imaging characteristics, and biopsy may disclose the nature of the lesion and prompt proper management. Coexistent renal cancer and RAML was found in 34 cases (1%) in nephrectomy or PN specimens carried out for renal masses pooled from multiple centers (89). The association was found in both sporadic and TSC AML and the most common pathologic type was clear cell RCC. In a cross-sectional study of asymptomatic patients with TSC, 2.2% had RCC (90). Even in the pediatric age group, one patient out of 145 with TSC-RAML developed RCC (30). In another study, a total of 54 RCC lesions were reported in 18 patients with TSC (91). Most of the lesions (94%) were associated with AML. RCC was commonly multiple synchronous, metachronous, and/or bilateral. The histologic types were chromophobe RCC (59%), RCC with smooth muscle stroma (30%), and granular eosinophilic type. A distinctive feature of all RCC lesions is negative HMB-45 immunostaining. RCC was more common in females (13:5), developed at an early age, and had an indolent course at a mean follow-up of 52 months. An unusually high prevalence of concurrent RCC and RAML was reported in none-TSC patients. In a retrospective study of nephrectomy specimens for sRAML, concurrent RCC was found in 47% of lesions mostly of clear cell type (56%) (92).

Epithelioid RAML

The diagnosis of epithelioid RAML is difficult because of the radiologic similarity to triphasic AML. Epithelioid AML (eAML) was reported in 7.7% of AML cases subjected to histopathologic diagnosis (93). eAML has an aggressive behavior, leading to metastasis, renal vein/inferior vena cava invasion, and in one study only 50% survival at 3 years (94). eAML has fewer or no fat content and is less frequently bilateral compared to classic AML. A study of a large series of patients with pure eAML reflected the aggressive behavior of the tumor in 41 patients (95). At the time of presentation, 79% patients were symptomatic and 12 (29.3%) patients had already metastasis. A follow-up of 33 patients (median 24.5 months) revealed recurrence in 17%, metastasis in 49%, and death in 33%. Another large series included 34 patients with eAML and atypia (96). Recurrence or metastasis was reported in 9 (26%) patients,

four of whom died from the disease by 34 months. The rather aggressive behavior reported in these series might be related to histological characteristics of the lesions. The malignant behavior of eAML might be predicted by the proportion of epithelioid cells, tumor necrosis, the degree of nuclear atypia, and mitosis (93). Other studies showed a lower rate of aggressive behavior. In one study, only 5 (6.4%) patients with RAML had an epithelioid histopathology and only one developed metastasis (97). In another study, only one patient developed metastasis out of 11 patients with eAML (98). A lower rate of metastatic behavior was reported in a large series of 20 patients with renal eAML where only one (5%) developed metastasis (99). The malignant potential of eAML might be related to p53 mutation (97, 100). Preoperative diagnosis of eAML might be confused with RCC, particularly in cases which present with venous extension or metastasis (101). Several studies tried in retrospect to provide radiologic characteristics that may predict the diagnosis of eAML and differentiate it from classic triphasic AML and RCC (98, 102–104). Fine-needle aspiration (FNA) diagnosis of AML is difficult when the epithelioid type predominates. A group of lesions that were subjected to FNA subsequently proved AML on histopathology (105). The diagnosis was possible in only half the lesions, while in nearly half of the lesions FNA was nondiagnostic or erroneous. It remains to be seen that prospectively any radiologic characteristics or techniques can provide an accurate preoperative diagnosis of eAML.

For such a dismal tumor, it is noteworthy to mention that case reports of everolimus treatment of eAML showed a dramatic response of the lesion and metastasis (106, 107). The role of such a treatment needs to be defined.

Renal Impairment

There is a plethora of evidence that associated renal impairment with RAML, particularly with TSC. In a cohort study, 16% of patients reached a chronic kidney disease (CKD) stage 3 or higher during a 12-year follow-up (108). A steeper yearly decline of glomerular filtration rate (GFR) was found in patients with TSC-RAML compared to the normal population (108). Age and RAML size correlated with CKD. The mortality rate was significantly higher in TSC patients (8.3%), mainly related to renal causes (2.6%), compared to the normal population (4.8%) (109). A meta-analysis confirmed that significantly more CKD is prevalent in TSC patients compared to age-matched population and there is a decrease in renal function as age increases (78). Moreover, renal causes accounted for 27.5% of the mortality reported in treated TSC patients (110). Several TSC patients have been treated in dialysis centers and some had high mortality (111, 112). Pediatric TSC patients may still develop renal insufficiency, though rarely (30).

Many review articles tried to explain the underlying pathology of renal impairment in patients with TSC (31, 113). Encroachment on the normal renal parenchyma or compression

was provided as a possible mechanism. These conclusions were based on a few original articles (110–112).

In a review of causes of mortality in patients with TSC, 40 deaths related to TSC in 355 cases were reported (110). Renal causes accounted for 11 (27.5%) of these deaths. Two patients died from hemorrhage, two from renal malignancy, and seven from renal failure. The authors state that renal failure may have occurred because of angiomyolipoma, renal cysts, or both. Indeed, in an earlier report from the same group, 80% of the 15 patients who died had cystic lesions alone or with angiomyolipoma and three patients died from polycystic kidney disease (PCK) (114). In another study, of 65 TSC patients treated in dialysis centers in France, AML alone accounted for 23.1% of cases, renal cysts for 18.5% of cases, AML with renal cysts for 53.8% of cases, and glomerulosclerosis and nephrocalcinosis for 4.6% of cases (111). Nephrectomy was carried out before dialysis in 21 (32.3%) patients and after dialysis in six patients. The indications of nephrectomy were severe hemorrhage in six patients, renal cancer in eight patients, and AML in 13 patients. Eight patients died: six related to dialysis, one related to untreated uremia, and one due to septic shock. The underlying pathology of end-stage renal failure in 10 patients with TSC treated in Europe was AML alone in one patient, four had PCK, one had AML with cysts, two had atrophic kidneys with cysts, one patient had adenocarcinoma, and in one patient pathology was unidentified (112).

Other studies have provided insights into the causes of renal impairment. In a cohort study documenting deterioration of renal function in TSC patients with RAML, there was a significant difference in CKD between patients who had embolization and those who did not have (108). A confounding factor of the association of larger RAML with CKD is that larger lesions are subjected to more interventions including higher embolization rate and nephrectomy (109). Another confounding factor is the association with renal cysts either as a part of RAML pathology or associated with adult PCK mutation. In an epidemiologic study of patients with TSC, patients who consented to have an ultrasound evaluation, 69% had RAML and 30% had renal cysts (115). In a cross-sectional study of asymptomatic patients with TSC, 61% of patients had a renal lesion, 49% had AML, 32% had renal cysts, and 2.2% had renal carcinoma (90). The patients with any renal lesions had cysts alone or associated with AML in 52.9%. Out of 45 patients who had a test for serum urea and creatinine, only four had elevated levels—three of them had cysts with or without AML lesions and one had only AML. The authors suggested that the presence of renal cysts contributed to the renal dysfunction, which was also endorsed by previous reports (116, 117). A possible mechanism is the concomitant deletions affecting the TSC2 and PKD1 genes on chromosome 16p (118).

Some reports indicated that intervention was not associated with renal impairment, while others showed that intervention/surgery rather than the AML lesions was associated

with deterioration of renal function (119, 120). The discrepancy may be related to the relative proportions of sporadic versus TSC-RAML, where most of the reports associating renal impairment with RAML involve TSC patients.

Analysis of data from the above articles may lead to the conclusion that indeed renal impairment is associated with RAML, particularly in the TSC patients. The underlying mechanisms, however, might be disputed. Renal cysts alone or with AML were the most common cause that contributed to renal failure, followed by nephrectomy and intervention. A smaller number of patients may have had renal impairment because of RAML alone; however, no evidence explaining the underlying pathogenesis was provided. The significance of this observation is that treatments that target reduction of renal failure in patients with RAML should primarily aim at the reduction of nephrectomy and intervention complications. Several novel approaches including mTOR inhibition may achieve this goal. Some patients will benefit from mTOR inhibition by reducing the size of RAML. It remains to be seen if any treatment may modify the progression of renal cysts which may have a greater impact on the development of renal failure.

Risks Related to Management

RAML may prompt intervention or surgery as a preventive or therapeutic measure. A prospective cohort study reported an intervention in 48.3% of patients with sRAML (29). The primary surgical intervention was indicated mainly for patients with fat-poor RAML (76.3%) and for lesions >4 cm; PN constituted 65.8% of the procedures. Primary embolization was scarcely used in the cohort (4.6%). Before January 2000, incidentally presenting lesions constituted 27.6% of patients and surgical extirpation constituted 28.6% of interventions; following that date, incidental presentation increased to 72.4% and surgery to 48.6%. Another study of patients with RAML reported 50.8% active treatment in the form of surgical intervention (79.8%) or embolization (20.2%) (120). At a mean follow-up of 64.8 months, 5.5% required additional intervention because of growth of lesions or hemorrhage. Others reported 48.3% interventions, 79.3% of which were PN or total nephrectomy (1). The indications for intervention were hemorrhage, pain, or suspicion of malignancy. Patients with TSC-RAML are particularly prone to such treatments. In a retrospective study of patients with TSC-RAML aged 18 years or older, 25% received an intervention. The reported rates included 17.1–18.5% embolization, 5.1–7.7% PN, 4.3–11.4% nephrectomy, 6.8–7.7% repeat embolization, and 1.7–4.5% repeat PN (121). These figures were reported before the use of mTOR inhibitors to treat similar patients.

Nephrectomy and PN

In the early days, surgical excision in the form of nephrectomy or PN of RAML was common for the management of

symptomatic cases (122), tumor hemorrhage, retroperitoneal hemorrhagic emergency (123), suspicion of malignancy (32), and later for prophylaxis. Surgical excision remains the only treatment that completely rids of the offending lesion, although recurrence from other parts of the kidney may occur. Nephrectomy or PN leads to loss of renal tissue, but in an emergency, a nephrectomy could be lifesaving. Preoperative embolization of the offending lesion may permit resuscitation and a well-planned PN and reduce the difficulty and complications of laparoscopic PN (124–126).

NSS was advocated for RAML at risk of bleeding for prophylaxis and for the suspicion of malignancy. PN, whether open surgical, laparoscopic, or robotic assisted, became the common urologic procedure. The challenges of surgery are related to high vascularity of RAML, producing difficulty that may lead to total nephrectomy and renal impairment that may develop with longer warm ischemia time. Several early series were reported utilizing NSS for RAML (33, 36, 127). Heidenreich et al. reported a summary of 10 series involving 101 patients prior to 2002 including their own (33). The indications for surgery were suspicion of malignancy, symptoms, or risk of bleeding. Early postoperative complications included a urinary leak in a minority of patients that required a secondary procedure. Renal function was maintained and no local recurrence was reported. An early series of open PN ($n = 58$, median size 3.9 cm) was reported including seven patients with multiple ipsilateral lesions, two patients with bilateral lesions, and four patients with solitary kidneys (36). Intraoperative blood transfusion was needed in 23% of cases. The early postoperative complication rate was 12.1%, most commonly due to ileus (8.6%) and urine leak (5.2%). At a median follow-up of 8 years, there were two AML recurrences (3.4%), no significant difference between preoperative and last serum creatinine was reported, and no *de novo* renal impairment was developed. A review of more contemporary series of NSS (2000–2010), open and laparoscopic, for RAML including 185 patients, reported higher complication rate (10.7–21.4% at mean follow-up of 26.4–96 months) and recurrence (3.4–5.9% at mean follow-up of 56.4–96 months) (4). Of these patients, 28 were also included in a previous review (33). Laparoscopic PN has similar surgical outcomes when performed for RAML in comparison to other renal tumors (38). At a median follow-up of 15 months, no AML recurrence or bleeding occurred. Lesion enucleation of large RAML ($n = 31$, range 9–15 cm) was carried out using an open technique (128). There was no significant change in perioperative creatinine. No complications or recurrences were reported. Retroperitoneal laparoscopy with enucleation of the lesions was described to minimize complications (129).

Robotic-assisted PN further facilitates the surgical procedure. In a multicenter study of robotic PN for patients with large RAML ($n = 40$, median diameter 7.2 cm) and challenging anatomical characteristics (median nephrometry score 9),

there were minimal perioperative complications and excellent renal function preservation (41). Preoperative embolization did not affect the outcome of the procedure. In another series reporting long-term follow-up of robotic PN for RAML ($n = 23$, median size 5.2 cm), at a median of 40 months follow-up, 86.9% of GFR was preserved and no long-term complications requiring secondary intervention or AML recurrence were reported (40). Robotic PN for smaller lesions ($n = 53$, median size 2.8 cm) included lesions suspicious for malignancy (79.2%), at risk of bleeding, or causing pain (39). Similarly, the procedure was associated with excellent preservation of renal function (median 91% preservation of GFR), no surgical complications requiring secondary intervention or recurrence of lesions.

In summary, NSS is associated with no or minimal recurrence of lesions, maintenance of renal function, and few manageable complications.

Embolization

A prophylactic embolization of lesions at high risk for bleeding became more common. The procedure is minimally invasive and has a high success rate (22, 42). Frequent retreatment, however, may be needed in nearly half of the patients and post-embolization syndrome affecting as high as 86% (22). A recent review of contemporary series of embolization for RAML was reported (4). Seven articles from 2009 to 2014 including 196 patients with a large mean lesion size ranging 7.8–15 cm reported a complication rate of 0–19.5%. Repeat embolization was needed in 5.9–56.3% of cases and surgery in 0–14.8% at a mean follow-up of 14–85.2 months. In a meta-analysis of patients who received selective embolization for RAML followed for 39 months, self-limiting postembolization syndrome occurred in 36%, another morbidity in 7%, and repeat embolization or surgery was needed in 21% (130). The recurrence rate might be higher in TSC patients (131). Loss of renal function consequently may be encountered. Several reports of embolization of RAML, however, reported no deterioration of renal function (23, 24, 132). Even with preexisting renal impairment, there was no significant change in renal function after embolization alone or associated with NSS (132). In another study, in patients with TSC-RAML, there was no significant deterioration of renal function attributed to prophylactic embolization (49). The presence of contralateral normal functioning kidney may mask renal damage occurring on the embolized kidney. To answer this question, a prospective study evaluated split renal function before and after embolization using radioisotope renography and found no significant change of renal function on the treated kidney (133).

mTOR inhibitors

Everolimus was approved for the treatment of TSC-associated RAML. No serious AE was encountered that required

cessation of treatment in the clinical trials (2, 77). AE included stomatitis, acne-like skin lesions, amenorrhea, irregular menstruation, and hypercholesterolemia. Open label extension of the clinical trial showed that everolimus is well tolerated and AE decreases over time (57). Other studies confirm the efficacy and safety of everolimus with manageable AE profile (134, 135). Lower doses were also shown to be effective. The significant reduction of lesion size was maintained for 36 months on a dose of 2.5–5 mg (136). A major concern for treating physicians is how long should the treatment continue as the effect of mTOR inhibition is reversible (75, 137). To continue the treatment for RAML, consideration should be given to long-term complications and the cost compared with other treatment modalities. The treating physician needs to observe metabolic complications that may cause dyslipidemia, hyperglycemia, immunosuppression-related complications, and fertility concerns and guide therapy accordingly (138). Several studies assessed the cost of health care for patients with TSC-RAML prior to approval of everolimus and found a high cost related to renal event management (108, 139, 140). A retrospective analysis of commercially insured and Medicaid patients in the United States compared claims related to TSC-RAML to controls between 2000 and 2012 (141). TSC was associated with higher incidence of hematuria, renal hemorrhage, CKD, renal failure, and hospital mortality than patients without TSC. The most significant differences were found in patients older than 18 years and for the incidence of hematuria and CKD. The health care annual cost was significantly higher for patients with TSC-RAML versus controls (142). Currently, it is not clear how everolimus treatment may impact the cost of TSC-RAML in the long term.

Risk of Associated Conditions

TSC-RAML, unlike its sporadic counterpart, is associated with a myriad of conditions that pose a significant risk to patients (143). Seizures, hydrocephalus, and intellectual disability are among the first presenting symptoms. The underlying neurological pathology includes cortical tubers, subependymal nodules, and giant cell astrocytomas. Other serious conditions that are commonly found are lymphangioleiomyomatosis of the lungs, cardiac rhabdomyoma, and hepatic AML. A cohort of adult women with TSC recruited by the NIH for the study of LAM had many patients with respiratory complications (75%), seizures (54%), renal intervention (43%), and mortality (12%) (144).

Conclusion

RAML encompasses a wide spectrum of small lesions that need not be followed to massive bilateral lesions that pose life-threatening risks to the patient. The disease itself or its treatment may contribute to the development of complications. With the development of interventional treatments,

minimally invasive surgery, and oral targeted therapy, there is hope that such complications can be reduced to a minimum and there will be better longevity and quality of life for patients even with the most significant disease burden.

Acknowledgments

The authors would like to thank Mr. Al Arjani, Turki, senior library assistant at the Health Sciences Library, Academic and Training Affairs for his valuable help in retrieving full-text articles.

Conflict of interest

The authors declare no potential conflicts of interest with respect to research, authorship, and/or publication of this article.

References

1. Seyam RM, Bissada NK, Kattan SA, Mokhtar AA, Aslam M, Fahmy WE, et al. Changing trends in presentation, diagnosis and management of renal angiomyolipoma: Comparison of sporadic and tuberous sclerosis complex-associated forms. *Urology*. 2008 Nov;72(5):1077–82. <http://dx.doi.org/10.1016/j.urology.2008.07.049>
2. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial. *Lancet Lond Engl*. 2013 Mar 9 ;381(9869):817–24. [http://dx.doi.org/10.1016/S0140-6736\(12\)61767-X](http://dx.doi.org/10.1016/S0140-6736(12)61767-X)
3. Peng Z, Yang L, Wang T, Han P, Liu Z, Wei Q. Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: A systematic review. *J Urol*. 2014 Nov;192(5):1424–30. <http://dx.doi.org/10.1016/j.juro.2014.04.096>
4. Flum AS, Hamoui N, Said MA, Yang XJ, Casalino DD, McGuire BB, et al. Update on the diagnosis and management of renal angiomyolipoma. *J Urol*. 2016 Apr;195(4 Pt 1):834–46. <http://dx.doi.org/10.1016/j.juro.2015.07.126>
5. Faddegon S, So A. Treatment of angiomyolipoma at a tertiary care centre: The decision between surgery and angiobolization. *Can Urol Assoc J J Assoc Urol Can*. 2011 Dec;5(6):E138–41. <http://dx.doi.org/10.5489/cuaj.10028>
6. Daskalopoulos G, Karyotis I, Heretis I, Anezinis P, Mavromanolakis E, Delakas D. Spontaneous perirenal hemorrhage: A 10-year experience at our institution. *Int Urol Nephrol*. 2004;36(1):15–19. <http://dx.doi.org/10.1023/B:UROL.0000032680.65742.9a>
7. Albi G, del Campo L, Tagarro D. Wunderlich's syndrome: Causes, diagnosis and radiological management. *Clin Radiol*. 2002 Sep;57(9):840–5. <http://dx.doi.org/10.1053/crad.2002.0981>
8. Nelson CP, Sanda MG. Contemporary diagnosis and management of renal angiomyolipoma. *J Urol*. 2002 Oct;168(4 Pt 1):1315–25. [http://dx.doi.org/10.1016/S0022-5347\(05\)64440-0](http://dx.doi.org/10.1016/S0022-5347(05)64440-0)
9. Lu C-Y, Min P-Q, Wu B. CT evaluation of spontaneously ruptured renal angiomyolipomas with massive hemorrhage spreading into multi-retroperitoneal fascia and fascial spaces. *Acta Radiol Short Rep*. 2012;1(4):1–6. <http://dx.doi.org/10.1258/arsr.2012.110009>

10. Yamakado K, Tanaka N, Nakagawa T, Kobayashi S, Yanagawa M, Takeda K. Renal angiomyolipoma: Relationships between tumor size, aneurysm formation, and rupture. *Radiology*. 2002 Oct;225(1):78–82. <http://dx.doi.org/10.1148/radiol.2251011477>
11. Champagnac J, Melodelima C, Martinelli T, Pagnoux G, Badet L, Juillard L, et al. Microaneurysms in renal angiomyolipomas: Can clinical and computed tomography features predict their presence and size? *Diagn Interv Imaging*. 2016 Mar;97(3):321–6. <http://dx.doi.org/10.1016/j.diii.2015.12.004>
12. Al-Ateeqi A, Ali RH, Kehinde EO, Mujaiabel K, Al-Hunayan A, Al-Harmi J. Increasing severity of haematuria with successive pregnancies in a woman with renal angiomyolipoma. *Int Urol Nephrol*. 2007;39(2):409–12. <http://dx.doi.org/10.1007/s11255-006-9036-2>
13. Tupikowski K, Bialy A, Dembowski J, Zlotkiewicz M, Guzinski M, Kolodziej AK, et al. Kidney angiomyolipoma in pregnancy. *Cent Eur J Urol*. 2014;66(4):434–6. <http://dx.doi.org/10.1016/j.jemermed.2011.05.059>
14. Hsu Y-P, Chen R-J, Fang J-F, Lin B-C. Traumatic rupture of renal angiomyolipoma managed with angioembolization followed by elective surgery: A report of two cases. *J Trauma*. 2005 Sep;59(3):737–41.
15. Zengin S, Al B, Yildirim C, Oktay MM, Yilmaz DA. Rupturing of renal angiomyolipoma due to physical examination. *BMJ Case Rep*. 2012 Jun 28. <http://dx.doi.org/10.1136/bcr.12.2011.5404>
16. Lai C-C, Fan W-C, Chao C-M, Liu W-L, Hou C-C. Traumatic rupture of a renal angiomyolipoma. *J Emerg Med*. 2012 Nov;43(5):e339–40. <http://dx.doi.org/10.1016/j.jemermed.2011.05.059>
17. Snow A, Halpenny D, McNeill G, Torreggiani WC. Life-threatening rupture of a renal angiomyolipoma in a patient taking over-the-counter horse chestnut seed extract. *J Emerg Med*. 2012 Dec;43(6):e401–3. <http://dx.doi.org/10.1016/j.jemermed.2010.11.044>
18. Wright T, Sooriakumaran P. Renal angiomyolipoma presenting with massive retroperitoneal haemorrhage due to deranged clotting factors: A case report. *Cases J*. 2008 Oct 4;1(1):213. <http://dx.doi.org/10.1186/1757-1626-1-213>
19. Andersen PE, Thorlund MG, Wennevik GE, Pedersen RL, Lund L. Interventional treatment of renal angiomyolipoma: Immediate results and clinical and radiological follow-up of 4.5 years. *Acta Radiol Open*. 2015 Jul;4(7):2058460115592442. <http://dx.doi.org/10.1177/2058460115592442>
20. Duan X-H, Zhang M-F, Ren J-Z, Han X-W, Chen P-F, Zhang K, et al. Urgent transcatheter arterial embolization for the treatment of ruptured renal angiomyolipoma with spontaneous hemorrhage. *Acta Radiol Stockh Swed* 1987. 2016 Nov;57(11):1360–5.
21. Chronopoulos PN, Kaisidis GN, Vaiopoulos CK, Perits DM, Varvarousis MN, Malioris AV, et al. Spontaneous rupture of a giant renal angiomyolipoma-Wunderlich's syndrome: Report of a case. *Int J Surg Case Rep*. 2016;19:140–3. <http://dx.doi.org/10.1016/j.ijscr.2015.12.017>
22. Wang C, Yang M, Tong X, Wang J, Guan H, Niu G, et al. Transarterial embolization for renal angiomyolipomas: A single centre experience in 79 patients. *J Int Med Res*. 2017 Apr;45(2):706–13. <http://dx.doi.org/10.1177/0300060516684251>
23. Bardin F, Chevallier O, Bertaut A, Delorme E, Moulin M, Pottecher P, et al. Selective arterial embolization of symptomatic and asymptomatic renal angiomyolipomas: A retrospective study of safety, outcomes and tumor size reduction. *Quant Imaging Med Surg*. 2017 Feb;7(1):8–23. <http://dx.doi.org/10.21037/qims.2017.01.02>
24. Urbano J, Paul L, Cabrera M, Alonso-Burgos A, Gomez D. Elective and emergency renal angiomyolipoma embolization with ethylene vinyl alcohol copolymer: Feasibility and initial experience. *J Vasc Interv Radiol JVIR*. 2017 Jun;28(6):832–9. <http://dx.doi.org/10.1016/j.jvir.2017.01.017>
25. Kuusk T, Biancari F, Lane B, Tobert C, Campbell S, Rimou U, et al. Treatment of renal angiomyolipoma: Pooled analysis of individual patient data. *BMC Urol*. 2015 Dec 28;15:123. <http://dx.doi.org/10.1186/s12894-015-0118-2>
26. Ouzaid I, Autorino R, Fatica R, Herts BR, McLennan G, Remer EM, et al. Active surveillance for renal angiomyolipoma: Outcomes and factors predictive of delayed intervention. *BJU Int*. 2014 Sep;114(3):412–17. [http://dx.doi.org/10.1016/S1569-9056\(14\)60089-0](http://dx.doi.org/10.1016/S1569-9056(14)60089-0)
27. Ljungberg B, Albiges L, Bensalah K, Bex A, Giles RH, Hora M, et al. European Association of Urology 2017 guidelines on renal cell cancer [Internet]. [cited 2017 Jul 25]. Available from: <http://uroweb.org/guideline/renal-cell-carcinoma/#3 B>
28. Krueger DA, Northrup H. Tuberous sclerosis complex surveillance and management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. *Pediatr Neurol*. 2013 Oct;49(4):255–65. <http://dx.doi.org/10.1016/j.pediatrneurol.2013.08.002>
29. Mues AC, Palacios JM, Haramis G, Casazza C, Badani K, Gupta M, et al. Contemporary experience in the management of angiomyolipoma. *J Endourol*. 2010 Nov;24(11):1883–6. <http://dx.doi.org/10.1089/end.2010.0223>
30. Warncke JC, Brodie KE, Grantham EC, Catarinicchia SP, Tong S, Kondo KL, et al. Pediatric renal angiomyolipomas in tuberous sclerosis complex. *J Urol*. 2017 Feb;197(2):500–6. <http://dx.doi.org/10.1016/j.juro.2016.09.082>
31. Kingswood JC, Bissler JJ, Budde K, Hulbert J, Guay-Woodford L, Sampson JR, et al. Review of the tuberous sclerosis renal guidelines from the 2012 consensus conference: Current data and future study. *Nephron*. 2016;134(2):51–8. <http://dx.doi.org/10.1159/000448293>
32. Yip SK, Tan PH, Cheng WS, Li MK, Foo KT. Surgical management of angiomyolipoma: Nephron-sparing surgery for symptomatic tumour. *Scand J Urol Nephrol*. 2000 Feb;34(1):32–5. <http://dx.doi.org/10.1080/003655900750016850>
33. Heidenreich A, Hegele A, Varga Z, von Knobloch R, Hofmann R. Nephron-sparing surgery for renal angiomyolipoma. *Eur Urol*. 2002 Mar;41(3):267–73. [http://dx.doi.org/10.1016/S0302-2838\(02\)00015-5](http://dx.doi.org/10.1016/S0302-2838(02)00015-5)
34. Patel U, Simpson E, Kingswood JC, Saggarr-Malik AK. Tuberose sclerosis complex: Analysis of growth rates aids differentiation of renal cell carcinoma from atypical or minimal-fat-containing angiomyolipoma. *Clin Radiol*. 2005 Jun;60(6):665–73; discussion 663–4. <http://dx.doi.org/10.1016/j.crad.2005.01.009>
35. Minervini A, Giubilei G, Masieri L, Lanzi F, Serni S, Carini M. Simple enucleation for the treatment of renal angiomyolipoma. *BJU Int*. 2007 Apr;99(4):887–91. <http://dx.doi.org/10.1111/j.1464-410X.2006.06702.x>
36. Boorjian SA, Frank I, Inman B, Lohse CM, Chevillie JC, Leibovich BC, et al. The role of partial nephrectomy for the management of sporadic renal angiomyolipoma. *Urology*. 2007 Dec;70(6):1064–8. <http://dx.doi.org/10.1016/j.urology.2007.07.045>
37. Simmons MN, Chung BI, Gill IS. Perioperative efficacy of laparoscopic partial nephrectomy for tumors larger than 4 cm. *Eur Urol*. 2009 Jan;55(1):199–207. <http://dx.doi.org/10.1016/j.eururo.2008.07.039>

38. Msezane L, Chang A, Shikanov S, Deklaj T, Katz MH, Shalhav AL, et al. Laparoscopic nephron-sparing surgery in the management of angiomyolipoma: A single center experience. *J Endourol.* 2010 Apr;24(4):583–7. <http://dx.doi.org/10.1089/end.2009.0330>
39. Kara O, Akca O, Zargar H, Andrade HS, Maurice MJ, Ramirez D, et al. Robotic partial nephrectomy in the treatment of renal angiomyolipoma. *J Endourol.* 2016 Mar;30(3):275–9. <http://dx.doi.org/10.1089/end.2015.0624>
40. Lin C-Y, Yang C-K, Ou Y-C, Chiu K-Y, Cheng C-L, Ho H-C, et al. Long-term outcome of robotic partial nephrectomy for renal angiomyolipoma. *Asian J Surg.* 2016 Dec 7. <http://dx.doi.org/10.1016/j.asjsur.2016.11.003>
41. Golan S, Johnson SC, Maurice MJ, Kaouk JH, Lai WR, Lee BR, et al. Safety and early effectiveness of robot-assisted partial nephrectomy for large angiomyolipomas. *BJU Int.* 2017 May;119(5):755–60. <http://dx.doi.org/10.1111/bju.13747>
42. Chick CM, Tan B-S, Cheng C, Taneja M, Lo R, Tan Y-H, et al. Long-term follow-up of the treatment of renal angiomyolipomas after selective arterial embolization with alcohol. *BJU Int.* 2010 Feb;105(3):390–4. <http://dx.doi.org/10.1111/j.1464-410X.2009.08813.x>
43. Chan CK, Yu S, Yip S, Lee P. The efficacy, safety and durability of selective renal arterial embolization in treating symptomatic and asymptomatic renal angiomyolipoma. *Urology.* 2011 Mar;77(3):642–8. <http://dx.doi.org/10.1016/j.urology.2010.08.040>
44. Ramon J, Rimon U, Garniek A, Golan G, Bensaid P, Kitrey ND, et al. Renal angiomyolipoma: Long-term results following selective arterial embolization. *Eur Urol.* 2009 May;55(5):1155–61. <http://dx.doi.org/10.1016/j.eururo.2008.04.025>
45. El Rafei M, Renard B, Puech P, Devos P, Gaillard V, Lemaitre L. Tumor necrosis after preventive embolization of large renal angiomyolipomas. *Diagn Interv Imaging.* 2015 Jun;96(6):579–87. <http://dx.doi.org/10.1016/j.diii.2015.01.008>
46. Hocquet A, Cornelis F, Le Bras Y, Meyer M, Tricaud E, Lasserre AS, et al. Long-term results of preventive embolization of renal angiomyolipomas: Evaluation of predictive factors of volume decrease. *Eur Radiol.* 2014 Aug;24(8):1785–93. <http://dx.doi.org/10.1007/s00330-014-3244-4>
47. Villalta JD, Sorensen MD, Durack JC, Kerlan RK, Stoller ML. Selective arterial embolization of angiomyolipomas: A comparison of smaller and larger embolic agents. *J Urol.* 2011 Sep;186(3):921–7. <http://dx.doi.org/10.1016/j.juro.2011.04.082>
48. Lee S-Y, Hsu H-H, Chen Y-C, Huang C-C, Wong Y-C, Wang L-J, et al. Embolization of renal angiomyolipomas: Short-term and long-term outcomes, complications, and tumor shrinkage. *Cardiovasc Intervent Radiol.* 2009 Nov;32(6):1171–8. <http://dx.doi.org/10.1007/s00270-009-9637-0>
49. Williams JM, Racadio JM, Johnson ND, Donnelly LF, Bissler JJ. Embolization of renal angiomyolipomata in patients with tuberous sclerosis complex. *Am J Kidney Dis Off J Natl Kidney Found.* 2006 Jan;47(1):95–102. <http://dx.doi.org/10.1053/j.ajkd.2005.09.028>
50. Bishay VL, Crino PB, Wein AJ, Malkowicz SB, Trerotola SO, Soulen MC, et al. Embolization of giant renal angiomyolipomas: Technique and results. *J Vasc Interv Radiol JVIR.* 2010 Jan;21(1):67–72. <http://dx.doi.org/10.1016/j.jvir.2009.09.020>
51. Steiner MS, Goldman SM, Fishman EK, Marshall FF. The natural history of renal angiomyolipoma. *J Urol.* 1993 Dec;150(6):1782–6. [http://dx.doi.org/10.1016/S0022-5347\(17\)35895-0](http://dx.doi.org/10.1016/S0022-5347(17)35895-0)
52. Bhatt JR, Richard PO, Kim NS, Finelli A, Manickavachagam K, Legere L, et al. Natural history of renal angiomyolipoma (AML): Most patients with large AMLs >4cm can be offered active surveillance as an initial management strategy. *Eur Urol.* 2016 Jul;70(1):85–90. <http://dx.doi.org/10.1016/j.eururo.2016.01.048>
53. De Luca S, Terrone C, Rossetti SR. Management of renal angiomyolipoma: A report of 53 cases. *BJU Int.* 1999 Feb;83(3):215–18. <http://dx.doi.org/10.1046/j.1464-410x.1999.00932.x>
54. Kennelly MJ, Grossman HB, Cho KJ. Outcome analysis of 42 cases of renal angiomyolipoma. *J Urol.* 1994 Dec;152(6 Pt 1):1988–91. [http://dx.doi.org/10.1016/S0022-5347\(17\)32286-3](http://dx.doi.org/10.1016/S0022-5347(17)32286-3)
55. Oesterling JE, Fishman EK, Goldman SM, Marshall FF. The management of renal angiomyolipoma. *J Urol.* 1986 Jun;135(6):1121–4. [http://dx.doi.org/10.1016/S0022-5347\(17\)46013-7](http://dx.doi.org/10.1016/S0022-5347(17)46013-7)
56. van Baal JG, Smits NJ, Keeman JN, Lindhout D, Verhoef S. The evolution of renal angiomyolipomas in patients with tuberous sclerosis. *J Urol.* 1994 Jul;152(1):35–8. [http://dx.doi.org/10.1016/S0022-5347\(17\)32809-4](http://dx.doi.org/10.1016/S0022-5347(17)32809-4)
57. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangiomyomatosis: Extension of a randomized controlled trial. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc—Eur Ren Assoc.* 2016 Jan;31(1):111–19.
58. Gyimadu AO, Kara O, Basaran D, Esinler I. Conservative management of a retroperitoneal hemorrhage following a ruptured renal angiomyolipoma in pregnancy. *J Obstet Gynaecol Res.* 2011 Feb;37(2):156–9. <http://dx.doi.org/10.1111/j.1447-0756.2010.01326.x>
59. dos Santos MML, Proenca SMS, Reis MINP de A, Viana RMAL, Martins LMB, Colaco JM dos R, et al. Spontaneous rupture of renal angiomyolipoma during pregnancy. *Rev Bras Ginecol E Obstet Rev Fed Bras Soc Ginecol E Obstet.* 2014 Aug;36(8):377–80. <http://dx.doi.org/10.1590/SO100-720320140005019>
60. Mishra VV, Mistry K, Nanda S, Choudhary S, Gandhi K. Successful pregnancy outcome in a patient with solitary kidney affected by angiomyolipoma: A rare case. *J Clin Diagn Res JCDR.* 2016 Oct;10(10):QD06–7.
61. Ao L, Ogasahara E, Okuda Y, Hirata S. Spontaneous rupture of renal angiomyolipoma during pregnancy. *BMJ Case Rep.* 2017 Jan 6. <http://dx.doi.org/10.1136/bcr-2016-217284>
62. Preece P, Mees B, Norris B, Christie M, Wagner T, Dundee P. Surgical management of haemorrhaging renal angiomyolipoma in pregnancy. *Int J Surg Case Rep.* 2015;7C:89–92. <http://dx.doi.org/10.1016/j.ijscr.2015.01.004>
63. Myoen S, Mitsuzuka K, Saito H, Ota H, Takase K, Arai Y. Spontaneous rupture of a renal angiomyolipoma at 25 weeks of pregnancy treated with transarterial embolization: A case report and review of the literature. *Int J Urol Off J Jpn Urol Assoc.* 2015 Jul;22(7):710–12. <http://dx.doi.org/10.1111/iju.12775>
64. Morales JP, Georganas M, Khan MS, Dasgupta P, Reidy JF. Embolization of a bleeding renal angiomyolipoma in pregnancy: Case report and review. *Cardiovasc Intervent Radiol.* 2005 Apr;28(2):265–8. <http://dx.doi.org/10.1007/s00270-004-1850-2>
65. Lee JD, Chang HC, Chu SH, Hsueh S, Soong YK. Massive retroperitoneal hemorrhage from spontaneous rupture of a renal angiomyolipoma during pregnancy. A case report. *J Reprod Med.* 1994 Jun;39(6):477–80.
66. Davis NF, Kelly R, Lee MJ, Mohan P. Selective arterial embolisation of bilateral angiomyolipomata in a symptomatic pregnant female. *BMJ Case Rep.* 2013 Nov 20. <http://dx.doi.org/10.1136/bcr-2013-009256>
67. Lucky MA, Shingler SN, Stephenson RN. A case report of spontaneous rupture of a renal angiomyolipoma in a post-partum. *Arch Gynecol Obstet.* 2009 Oct;280(4):643–5. <http://dx.doi.org/10.1007/s00404-009-0964-9>

68. Orywal AK, Zeile M, Bruning R, Gross AJ, Netsch C. Rupture of renal angiomyolipoma during childbirth. *Urology*. 2015 Apr;85(4):e19–20. <http://dx.doi.org/10.1016/j.urology.2014.12.008>
69. Tanaka M, Kyo S, Inoue M, Kojima T. Conservative management and vaginal delivery following ruptured renal angiomyolipoma. *Obstet Gynecol*. 2001 Nov;98(5 Pt 2):932–3.
70. Lopater J, Hartung O, Bretelle F, Bastide C. Management of angiomyolipoma vena cava thrombus during pregnancy. *Obstet Gynecol*. 2011 Feb;117(2 Pt 2):440–3. <http://dx.doi.org/10.1097/AOG.0b013e3181edbc56>
71. Govednik-Horny C, Atkins M. Angiomyolipoma with vascular invasion during pregnancy. *Ann Vasc Surg*. 2011 Nov;25(8):1138.e9–13. <http://dx.doi.org/10.1016/j.avsg.2011.05.023>
72. Cleary-Goldman J, Sanghvi AV, Nakhuda GS, Robinson JN. Conservative management of pulmonary lymphangiomyomatosis and tuberous sclerosis complicated by renal angiomyolipomas in pregnancy. *J Matern -Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet*. 2004 Feb;15(2):132–4.
73. Peces R, Cuesta-Lopez E, Peces C, Selgas R. Giant bilateral renal angiomyolipomas and lymphangiomyomatosis presenting after two successive pregnancies successfully treated with surgery and rapamycin. *ScientificWorldJournal*. 2011;11:2115–23. <http://dx.doi.org/10.1100/2011/263137>
74. Iruloh C, Keriakos R, Smith DJ, Cleveland T. Renal angiomyolipoma and lymphangiomyomatosis in pregnancy. *J Obstet Gynaecol J Inst Obstet Gynaecol*. 2013 Aug;33(6):542–6. <http://dx.doi.org/10.3109/01443615.2013.812622>
75. Dabora SL, Franz DN, Ashwal S, Sagalowsky A, DiMario FJJ, Miles D, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: Kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. *PLoS One*. 2011;6(9):e23379. <http://dx.doi.org/10.1371/journal.pone.0023379>
76. Cabrera-Lopez C, Marti T, Catala V, Torres F, Mateu S, Ballarin J, et al. Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: A two years trial. *Orphanet J Rare Dis*. 2012 Nov 11;7:87. <http://dx.doi.org/10.1186/1750-1172-7-87>
77. Kingswood JC, Jozwiak S, Belousova ED, Frost MD, Kuperman RA, Bebin EM, et al. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: Subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc—Eur Ren Assoc*. 2014 Jun;29(6):1203–10.
78. Bissler JJ, Kingswood JC. Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: A systematic review. *Ther Adv Urol*. 2016 Aug;8(4):279–90. <http://dx.doi.org/10.1177/1756287216641353>
79. Bauman TM, Potretzke AM, Wright AJ, Vetter JM, Potretzke TA, Figenshau RS. Patient and nonradiographic tumor characteristics predicting lipid-poor angiomyolipoma in small renal masses: Introducing the BEARS index. *Investig Clin Urol*. 2017 Jul;58(4):235–40. <http://dx.doi.org/10.4111/icu.2017.58.4.235>
80. Lane BR, Aydin H, Danforth TL, Zhou M, Remer EM, Novick AC, et al. Clinical correlates of renal angiomyolipoma subtypes in 209 patients: Classic, fat poor, tuberous sclerosis associated and epithelioid. *J Urol*. 2008 Sep;180(3):836–43. <http://dx.doi.org/10.1016/j.juro.2008.05.041>
81. Lu Q, Wang W, Huang B, Li C, Li C. Minimal fat renal angiomyolipoma: The initial study with contrast-enhanced ultrasonography. *Ultrasound Med Biol*. 2012 Nov;38(11):1896–901. <http://dx.doi.org/10.1016/j.ultrasmed-bio.2012.07.014>
82. Tanaka H, Fujii Y, Tanaka H, Ishioka J, Matsuoka Y, Saito K, et al. Stepwise algorithm using computed tomography and magnetic resonance imaging for diagnosis of fat-poor angiomyolipoma in small renal masses: Development and external validation. *Int J Urol Off J Jpn Urol Assoc*. 2017 Jul;24(7):511–17. <http://dx.doi.org/10.1111/iju.13354>
83. Kim YH, Han K, Oh YT, Jung DC, Cho NH, Park SY. Morphologic analysis with computed tomography may help differentiate fat-poor angiomyolipoma from renal cell carcinoma: A retrospective study with 602 patients. *Abdom Radiol N Y*. 2017 Jul 4. <http://dx.doi.org/10.1007/s00261-017-1244-y>
84. Jhaveri KS, Elmi A, Hosseini-Nik H, Hedgire S, Evans A, Jewett M, et al. Predictive value of chemical-shift MRI in distinguishing clear cell renal cell carcinoma from non-clear cell renal cell carcinoma and minimal-fat angiomyolipoma. *AJR Am J Roentgenol*. 2015 Jul;205(1):W79–86. <http://dx.doi.org/10.2214/AJR.14.13245>
85. Schieda N, Dilauro M, Moosavi B, Hodgdon T, Cron GO, McInnes MDF, et al. MRI evaluation of small (<4cm) solid renal masses: Multivariate modeling improves diagnostic accuracy for angiomyolipoma without visible fat compared to univariate analysis. *Eur Radiol*. 2016 Jul;26(7):2242–51. <http://dx.doi.org/10.1007/s00330-015-4039-y>
86. Jeong CJ, Park BK, Park JJ, Kim CK. Unenhanced CT and MRI parameters that can be used to reliably predict fat-invisible angiomyolipoma. *AJR Am J Roentgenol*. 2016 Feb;206(2):340–7. <http://dx.doi.org/10.2214/AJR.15.15086>
87. Park JJ, Kim CK. Small (<4 cm) renal tumors with predominantly low signal intensity on. *AJR Am J Roentgenol*. 2017 Jan;208(1):124–30. <http://dx.doi.org/10.2214/AJR.16.16102>
88. Potretzke AM, Potretzke TA, Bauman TM, Knight BA, Park AM, Mobley JM, et al. Computed tomography and magnetic resonance findings of fat-poor angiomyolipomas. *J Endourol*. 2017 Feb;31(2):119–28. <http://dx.doi.org/10.1089/end.2016.0219>
89. Jimenez RE, Eble JN, Reuter VE, Epstein JI, Folpe AL, de Peralta-Venturina M, et al. Concurrent angiomyolipoma and renal cell neoplasia: A study of 36 cases. *Mod Pathol Off J U S Can Acad Pathol Inc*. 2001 Mar;14(3):157–63. <http://dx.doi.org/10.1038/modpathol.3880275>
90. Cook JA, Oliver K, Mueller RF, Sampson J. A cross sectional study of renal involvement in tuberous sclerosis. *J Med Genet*. 1996 Jun;33(6):480–4. <http://dx.doi.org/10.1136/jmg.33.6.480>
91. Guo J, Tretiakova MS, Troxell ML, Osunkoya AO, Fadare O, Sangoi AR, et al. Tuberous sclerosis-associated renal cell carcinoma: A clinicopathologic study of 57 separate carcinomas in 18 patients. *Am J Surg Pathol*. 2014 Nov;38(11):1457–67. <http://dx.doi.org/10.1097/PAS.0000000000000248>
92. Mei M, Rosen LE, Reddy V, Cimaluk DJ, Gattuso P. Concurrent angiomyolipomas and renal cell neoplasms in patients without tuberous sclerosis: A retrospective study. *Int J Surg Pathol*. 2015 Jun;23(4):265–70. <http://dx.doi.org/10.1177/1066896915569914>
93. Aydin H, Magi-Galluzzi C, Lane BR, Sercia L, Lopez JI, Rini BI, et al. Renal angiomyolipoma: Clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association. *Am J Surg Pathol*. 2009 Feb;33(2):289–97. <http://dx.doi.org/10.1097/PAS.0b013e31817ed7a6>
94. Delhorme J-B, Fontana A, Levy A, Terrier P, Fiore M, Tzannis D, et al. Renal angiomyolipomas: At least two diseases. A series of patients treated at two European institutions. *Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol*. 2017 Apr;43(4):831–6. <http://dx.doi.org/10.1016/j.ejso.2016.11.012>
95. Nese N, Martignoni G, Fletcher CD, Gupta R, Pan C-C, Kim H, et al. Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41

- cases: Detailed assessment of morphology and risk stratification. *Am J Surg Pathol*. 2011 Feb;35(2):161–76. <http://dx.doi.org/10.1097/PAS.0b013e318206f2a9>
96. Brimo F, Robinson B, Guo C, Zhou M, Latour M, Epstein JI. Renal epithelioid angiomyolipoma with atypia: A series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy. *Am J Surg Pathol*. 2010 May;34(5):715–22. <http://dx.doi.org/10.1097/PAS.0b013e3181d90370>
 97. Park JH, Lee C, Suh JH, Kim G, Song B, Moon KC. Renal epithelioid angiomyolipoma: Histopathologic review, immunohistochemical evaluation and prognostic significance. *Pathol Int*. 2016 Oct;66(10):571–7. <http://dx.doi.org/10.1111/pin.12458>
 98. Zheng S, Bi X, Song Q, Yuan Z, Guo L, Zhang H, et al. A suggestion for pathological grossing and reporting based on prognostic indicators of malignancies from a pooled analysis of renal epithelioid angiomyolipoma. *Int Urol Nephrol*. 2015 Oct;47(10):1643–51. <http://dx.doi.org/10.1007/s11255-015-1079-9>
 99. He W, Chevillet JC, Sadow PM, Gopalan A, Fine SW, Al-Ahmadie HA, et al. Epithelioid angiomyolipoma of the kidney: Pathological features and clinical outcome in a series of consecutively resected tumors. *Mod Pathol Off J U S Can Acad Pathol Inc*. 2013 Oct;26(10):1355–64. <http://dx.doi.org/10.1038/modpathol.2013.72>
 100. Li W, Guo L, Bi X, Ma J, Zheng S. Immunohistochemistry of p53 and Ki-67 and p53 mutation analysis in renal epithelioid angiomyolipoma. *Int J Clin Exp Pathol*. 2015;8(8):9446–51.
 101. Hassan M, El-Hefnawy AS, Elshal AM, Mosbah A, El-Baz M, Shaaban A. Renal epithelioid angiomyolipoma: A rare variant with unusual behavior. *Int Urol Nephrol*. 2014 Feb;46(2):317–22. <http://dx.doi.org/10.1007/s11255-013-0510-3>
 102. Cui L, Zhang J-G, Hu X-Y, Fang X-M, Lerner A, Yao X-J, et al. CT imaging and histopathological features of renal epithelioid angiomyolipomas. *Clin Radiol*. 2012 Dec;67(12):e77–82. <http://dx.doi.org/10.1016/j.crad.2012.08.006>
 103. Lu Q, Li C, Huang B, Xue L, Wang W. Triphasic and epithelioid minimal fat renal angiomyolipoma and clear cell renal cell carcinoma: Qualitative and quantitative CEUS characteristics and distinguishing features. *Abdom Imaging*. 2015 Feb;40(2):333–42. <http://dx.doi.org/10.1007/s00261-014-0221-y>
 104. Liu Y, Qu F, Cheng R, Ye Z. CT-imaging features of renal epithelioid angiomyolipoma. *World J Surg Oncol*. 2015 Sep 22;13:280. <http://dx.doi.org/10.1186/s12957-015-0700-9>
 105. Zhou H, Guo M, Gong Y. Challenge of FNA diagnosis of angiomyolipoma: A study of 33 cases. *Cancer*. 2017 Apr;125(4):257–66. <http://dx.doi.org/10.1002/cncy.21824>
 106. Kohno J, Matsui Y, Yamasaki T, Shibasaki N, Kamba T, Yoshimura K, et al. Role of mammalian target of rapamycin inhibitor in the treatment of metastatic epithelioid angiomyolipoma: A case report. *Int J Urol Off J Jpn Urol Assoc*. 2013 Sep;20(9):938–41. <http://dx.doi.org/10.1111/iju.12095>
 107. Shitara K, Yatabe Y, Mizota A, Sano T, Nimura Y, Muro K. Dramatic tumor response to everolimus for malignant epithelioid angiomyolipoma. *Jpn J Clin Oncol*. 2011 Jun;41(6):814–16. <http://dx.doi.org/10.1093/jjco/hyr035>
 108. Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, van Waalwijk van Doorn Khosrovani SB, et al. Kidney involvement in tuberous sclerosis complex: The impact on healthcare resource use and costs. *J Med Econ*. 2015;18(12):1060–70. <http://dx.doi.org/10.3111/13696998.2015.1075995>
 109. Eijkemans MJC, van der Wal W, Reijnders LJ, Roes KCB, van Waalwijk van Doorn Khosrovani SB, Pelletier C, et al. Long-term follow-up assessing renal angiomyolipoma treatment patterns, morbidity, and mortality: An observational study in tuberous sclerosis complex patients in the Netherlands. *Am J Kidney Dis Off J Natl Kidney Found*. 2015 Oct;66(4):638–45. <http://dx.doi.org/10.1053/j.ajkd.2015.05.016>
 110. Shepherd CW, Gomez MR. Mortality in the Mayo Clinic tuberous sclerosis complex study. *Ann N Y Acad Sci*. 1991;615:375–7. <http://dx.doi.org/10.1111/j.1749-6632.1991.tb37786.x>
 111. Schillinger F, Montagnac R. Chronic renal failure and its treatment in tuberous sclerosis. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc—Eur Ren Assoc*. 1996 Mar;11(3):481–5.
 112. Clarke A, Hancock E, Kingswood C, Osborne JP. End-stage renal failure in adults with the tuberous sclerosis complex. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc—Eur Ren Assoc*. 1999 Apr;14(4):988–91.
 113. Bissler JJ, Kingswood JC. Renal angiomyolipomata. *Kidney Int*. 2004 Sep;66(3):924–34. <http://doi.org/10.1111/j.1523-1755.2004.00838.x>
 114. Stillwell TJ, Gomez MR, Kelalis PP. Renal lesions in tuberous sclerosis. *J Urol*. 1987 Sep;138(3):477–81. [http://dx.doi.org/10.1016/S0022-5347\(17\)43234-4](http://dx.doi.org/10.1016/S0022-5347(17)43234-4)
 115. O’Callaghan FJ, Noakes MJ, Martyn CN, Osborne JP. An epidemiological study of renal pathology in tuberous sclerosis complex. *BJU Int*. 2004 Oct;94(6):853–7. <http://dx.doi.org/10.1111/j.1464-410X.2004.05046.x>
 116. Okada RD, Platt MA, Fleishman J. Chronic renal failure in patients with tuberous sclerosis. Association with renal cysts. *Nephron*. 1982;30(1):85–8. <http://dx.doi.org/10.1159/000182439>
 117. Yu DT, Sheth KJ. Cystic renal involvement in tuberous sclerosis. *Clin Pediatr (Phila)*. 1985 Jan;24(1):36–9. <http://dx.doi.org/10.1177/000992288502400108>
 118. Brook-Carter PT, Peral B, Ward CJ, Thompson P, Hughes J, Maheshwar MM, et al. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease—A contiguous gene syndrome. *Nat Genet*. 1994 Dec;8(4):328–32. <http://dx.doi.org/10.1038/ng1294-328>
 119. Seyam R, Khudair WA, Kattan SA, Al Otaibi MF, Skaff F, Al-Taweel WM. The impact of renal angiomyolipoma on estimated glomerular filtration rate in patients with tuberous sclerosis complex. *Ann Saudi Med*. 2016 Oct;36(5):356–63. <http://dx.doi.org/10.5144/0256-4947.2016.356>
 120. Koo KC, Kim WT, Ham WS, Lee JS, Ju HJ, Choi YD. Trends of presentation and clinical outcome of treated renal angiomyolipoma. *Yonsei Med J*. 2010 Sep;51(5):728–34. <http://dx.doi.org/10.3349/ymj.2010.51.5.728>
 121. Bissler J, Cappell K, Charles H, Song X, Liu Z, Prestifilippo J, et al. Rates of interventional procedures in patients with tuberous sclerosis complex-related renal angiomyolipoma. *Curr Med Res Opin*. 2015 Aug;31(8):1501–7. <http://dx.doi.org/10.1185/03007995.2015.1060212>
 122. Tong YC, Chieng PU, Tsai TC, Lin SN. Renal angiomyolipoma: Report of 24 cases. *Br J Urol*. 1990 Dec;66(6):585–9. <http://dx.doi.org/10.1111/j.1464-410X.1990.tb07187.x>
 123. Ou YC, Wu HC, Yang CR, Chang CL, Hwang TI, Chang CH. Renal angiomyolipoma: Experience of 23 patients. *Zhonghua Yi Xue Za Zhi Chin Med J Free China Ed*. 1991 Sep;48(3):217–23.
 124. Jou Y-C, Chen W-P, Huang C-L. Urgent angiobolization with early elective nephron-sparing surgery for spontaneously ruptured renal angiomyolipoma. *J Chin Med Assoc J CMA*. 2009 Aug;72(8):450–2. [http://dx.doi.org/10.1016/S1726-4901\(09\)70405-8](http://dx.doi.org/10.1016/S1726-4901(09)70405-8)
 125. Wang D, Li H-Z, Ji Z-G. Effectiveness and safety of laparoscopic enucleation combined with selective arterial embolization for renal angiomyolipoma. *Cancer Biomark Sect Dis Markers*. 2017;19(2):177–83. <http://dx.doi.org/10.3233/CBM-160501>

126. Qin C, Wang Y, Li P, Li P, Tao J, Shao P, et al. Super-selective artery embolization before laparoscopic partial nephrectomy in treating renal angiomyolipoma. *Urol Int*. 2017 Apr 14. <http://dx.doi.org/10.1159/000472261>
127. Fazeli-Matin S, Novick AC. Nephron-sparing surgery for renal angiomyolipoma. *Urology*. 1998 Oct;52(4):577–83. [http://dx.doi.org/10.1016/S0090-4295\(98\)00236-2](http://dx.doi.org/10.1016/S0090-4295(98)00236-2)
128. Siena G, Minervini A, Tuccio A, Vittori G, Salvi M, Sebastianelli A, et al. Nephron-sparing surgery for giant angiomyolipomas of kidney. *Arch Ital Urol Androl Organo Uff Soc Ital Ecogr Urol E Nefrol*. 2012 Sep;84(3):146–50.
129. Liu W, Qi L, Chen M, Wang L, Liu L, Zhu B, et al. Laparoscopic retroperitoneal enucleation-separation surgery for renal angiomyolipoma: Perioperative and oncologic outcomes based on a randomized controlled trial. *J Endourol*. 2016 Aug;30(8):901–5. <http://dx.doi.org/10.1089/end.2016.0195>
130. Murray TE, Doyle F, Lee M. Transarterial embolization of angiomyolipoma: A systematic review. *J Urol*. 2015 Sep;194(3):635–9. <http://dx.doi.org/10.1016/j.juro.2015.04.081>
131. Kothary N, Soulen MC, Clark TWI, Wein AJ, Shlansky-Goldberg RD, Crino PB, et al. Renal angiomyolipoma: Long-term results after arterial embolization. *J Vasc Interv Radiol JVIR*. 2005 Jan;16(1):45–50. <http://dx.doi.org/10.1097/01.RVI.0000143769.79774.70>
132. Lee S-Y, Hsu H-H, Chen Y-C, Huang C-C, Wong Y-C, Wang L-J, et al. Evaluation of renal function of angiomyolipoma patients after selective transcatheter arterial embolization. *Am J Med Sci*. 2009 Feb;337(2):103–8. <http://dx.doi.org/10.1097/MAJ.0b013e31817f6dd9>
133. Baba Y, Hayashi S, Ikeda S, Jinguji M, Nakajo M, Nakajo M. Evaluation of split renal function before and after renal arterial embolization for angiomyolipoma using absolute ethanol. *Cardiovasc Intervent Radiol*. 2014 Oct;37(5):1220–5. <http://dx.doi.org/10.1007/s00270-013-0780-2>
134. Hatano T, Chikaraishi K, Inaba H, Endo K, Egawa S. Outcomes of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: A single institution experience in Japan. *Int J Urol Off J Jpn Urol Assoc*. 2016 Oct;23(10):833–8. <http://dx.doi.org/10.1111/iju.13168>
135. Robles NR, Peces R, Gomez-Ferrer A, Villacampa F, Alvarez-Ossorio JL, Perez-Segura P, et al. Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: A Spanish expanded access trial. *Orphanet J Rare Dis*. 2016 Sep 26;11(1):128. <http://dx.doi.org/10.1186/s13023-016-0517-9>
136. Tsai J-D, Wei C-C, Yang S-H, Fan H-C, Hsu C-C, Tung M-C, et al. The effects of everolimus on tuberous sclerosis complex-associated renal angiomyolipoma: A preliminary report. *Nephrol Carlton Vic*. 2016 Aug 27. <http://dx.doi.org/10.1111/nep.12912>
137. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangiomyomatosis. *N Engl J Med*. 2008 Jan 10;358(2):140–51. <http://dx.doi.org/10.1056/NEJMoa063564>
138. Davies M, Saxena A, Kingswood JC. Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: A practical guide. *Orphanet J Rare Dis*. 2017 Feb 15;12(1):35. <http://dx.doi.org/10.1186/s13023-017-0581-9>
139. Kingswood JC, Crawford P, Johnson SR, Sampson JR, Shepherd C, Demuth D, et al. The economic burden of tuberous sclerosis complex in the UK: A retrospective cohort study in the clinical practice research datalink. *J Med Econ*. 2016 Nov;19(11):1087–98. <http://dx.doi.org/10.1080/13696998.2016.1199432>
140. Kingswood JC, Nasuti P, Patel K, Myland M, Siva V, Gray E. The economic burden of tuberous sclerosis complex in UK patients with renal manifestations: A retrospective cohort study in the clinical practice research datalink (CPRD). *J Med Econ*. 2016 Dec;19(12):1116–26. <http://dx.doi.org/10.1080/13696998.2016.1202254>
141. Bissler J, Cappell K, Charles H, Song X, Liu Z, Prestifilippo J, et al. Long-term clinical morbidity in patients with renal angiomyolipoma associated with tuberous sclerosis complex. *Urology*. 2016 Sep;95:80–7. <http://dx.doi.org/10.1016/j.urology.2016.04.027>
142. Song X, Liu Z, Cappell K, Gregory C, Said Q, Prestifilippo J, et al. Healthcare utilization and costs in patients with tuberous sclerosis-complex-related renal angiomyolipoma. *J Med Econ*. 2017 Apr;20(4):388–94. <http://dx.doi.org/10.1080/13696998.2016.1272461>
143. Kingswood JC, d'Augeres GB, Belousova E, Ferreira JC, Carter T, Castellana R, et al. Tuberous sclerosis registry to increase disease Awareness (TOSCA)—Baseline data on 2093 patients. *Orphanet J Rare Dis*. 2017 Jan 5;12(1):2. <http://dx.doi.org/10.1186/s13023-016-0553-5>
144. Seibert D, Hong C-H, Takeuchi F, Olsen C, Hathaway O, Moss J, et al. Recognition of tuberous sclerosis in adult women: Delayed presentation with life-threatening consequences. *Ann Intern Med*. 2011 Jun 21;154(12):806–13, W-294.